• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Regression of Infantile Glioblastoma After First-Line Treatment With Larotrectinib.

作者信息

Alharbi Musa, Mobark Nahla Ali, Balbaid Ali Abdullah O, Alanazi Fatmah A, Aljabarat Wael Abdel Rahman, Bakhsh Eman A, Ramkissoon Shakti H, Abedalthagafi Malak

机构信息

Department of Paediatric Oncology, Comprehensive Cancer Centre, King Fahad Medical, Riyadh, Saudi Arabia.

Radiation Oncology Department, Comprehensive Cancer Centre, King Fahad Medical City, Riyadh, Saudi Arabia.

出版信息

JCO Precis Oncol. 2020 Jun 30;4. doi: 10.1200/PO.20.00017. eCollection 2020.

DOI:10.1200/PO.20.00017
PMID:32923892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7446437/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6717/7446437/f252823e3346/PO.20.00017f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6717/7446437/b7eb11587fe2/PO.20.00017f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6717/7446437/f252823e3346/PO.20.00017f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6717/7446437/b7eb11587fe2/PO.20.00017f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6717/7446437/f252823e3346/PO.20.00017f2.jpg

相似文献

1
Regression of Infantile Glioblastoma After First-Line Treatment With Larotrectinib.一线使用拉罗替尼治疗后小儿胶质母细胞瘤的消退
JCO Precis Oncol. 2020 Jun 30;4. doi: 10.1200/PO.20.00017. eCollection 2020.
2
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.婴儿复发性、化疗耐药性婴儿纤维肉瘤携带特征性 ETV6-NTRK3 基因融合，对 TRK 抑制剂拉罗替尼快速、完全和持续的肿瘤反应。
Ann Oncol. 2019 Nov;30 Suppl 8:viii31-viii35. doi: 10.1093/annonc/mdz382. Epub 2019 Dec 24.
3
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.婴儿复发性、化疗耐药性婴儿纤维肉瘤携带特征性 ETV6-NTRK3 基因融合，对 TRK 抑制剂拉罗替尼快速、完全和持续的肿瘤应答。
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii31-viii35. doi: 10.1093/annonc/mdz382.
4
Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma.先天性中胚层肾瘤t(12;15)与ETV6-NTRK3基因融合相关：与先天性（婴儿型）纤维肉瘤的细胞遗传学及分子关系
Am J Pathol. 1998 Nov;153(5):1451-8. doi: 10.1016/S0002-9440(10)65732-X.
5
Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues.先天性婴儿纤维肉瘤：10例临床病理研究及应用石蜡包埋组织对ETV6-NTRK3融合转录本进行分子检测
Am J Clin Pathol. 2001 Mar;115(3):348-55. doi: 10.1309/3H24-E7T7-V37G-AKKQ.
6
Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors.ETV6-NTRK3基因融合的分子检测可将先天性纤维肉瘤与其他儿童期梭形细胞肿瘤区分开来。
Am J Surg Pathol. 2000 Jul;24(7):937-46. doi: 10.1097/00000478-200007000-00005.
7
Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST.转录组测序鉴定出 ETV6-NTRK3 为 GIST 中涉及的基因融合。
J Pathol. 2016 Mar;238(4):543-9. doi: 10.1002/path.4677. Epub 2016 Jan 25.
8
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.先天性纤维肉瘤中的一种新型ETV6-NTRK3基因融合
Nat Genet. 1998 Feb;18(2):184-7. doi: 10.1038/ng0298-184.
9
Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src.ETV6-NTRK3嵌合酪氨酸激酶引起的细胞转化及磷酸肌醇-3-激酶-Akt级联反应的激活需要c-Src。
Cancer Res. 2007 Apr 1;67(7):3192-200. doi: 10.1158/0008-5472.CAN-06-3526.
10
Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children's Oncology Group study.婴儿纤维肉瘤中受体酪氨酸激酶激活的介质：儿童肿瘤学组的一项研究。
J Pathol. 2012 Sep;228(1):119-30. doi: 10.1002/path.4010. Epub 2012 Jul 2.

引用本文的文献

1
TRK Inhibitors in Adult and Pediatric High-Grade Gliomas: A Systematic Review and Individual Participant Data Meta-Analysis.成人和儿童高级别胶质瘤中的TRK抑制剂：系统评价与个体参与者数据荟萃分析
Cancers (Basel). 2025 Jun 23;17(13):2089. doi: 10.3390/cancers17132089.
2
Rare variant of large pediatric glioneuronal tumor with novel MYO5A::NTRK3 fusion: illustrative case.具有新型MYO5A::NTRK3融合的小儿大型神经胶质神经元肿瘤罕见变异型：病例说明
J Neurosurg Case Lessons. 2024 Mar 4;7(10). doi: 10.3171/CASE23638.
3
Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategies.

本文引用的文献

1
Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia.沙特阿拉伯儿科低级别胶质瘤的临床管理和基因组分析。
PLoS One. 2020 Jan 29;15(1):e0228356. doi: 10.1371/journal.pone.0228356. eCollection 2020.
2
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.婴儿复发性、化疗耐药性婴儿纤维肉瘤携带特征性 ETV6-NTRK3 基因融合，对 TRK 抑制剂拉罗替尼快速、完全和持续的肿瘤应答。
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii31-viii35. doi: 10.1093/annonc/mdz382.
3
胶质母细胞瘤中预测性协同多靶点治疗的筛选确定了新的治疗策略。
Neurooncol Adv. 2023 Jun 13;5(1):vdad073. doi: 10.1093/noajnl/vdad073. eCollection 2023 Jan-Dec.
4
A comprehensive analysis of infantile central nervous system tumors to improve distinctive criteria for infant-type hemispheric glioma versus desmoplastic infantile ganglioglioma/astrocytoma.全面分析婴儿中枢神经系统肿瘤，以提高婴儿型大脑半球胶质瘤与促结缔组织增生性婴儿型节细胞胶质瘤/星形细胞瘤的鉴别标准。
Brain Pathol. 2023 Sep;33(5):e13182. doi: 10.1111/bpa.13182. Epub 2023 Jun 22.
5
Role of Molecular Targeted Therapeutic Drugs in Treatment of Glioblastoma: A Review Article.分子靶向治疗药物在胶质母细胞瘤治疗中的作用：一篇综述文章。
Glob Med Genet. 2023 Apr 17;10(2):42-47. doi: 10.1055/s-0043-57028. eCollection 2023 Jun.
6
Signaling pathways in brain tumors and therapeutic interventions.脑肿瘤中的信号通路与治疗干预。
Signal Transduct Target Ther. 2023 Jan 4;8(1):8. doi: 10.1038/s41392-022-01260-z.
7
NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series.实体瘤中的NTRK基因融合与TRK抑制剂：病例报告和病例系列的系统评价
J Pers Med. 2022 Nov 2;12(11):1819. doi: 10.3390/jpm12111819.
8
Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory fusion glioblastoma.恩曲替尼在一例放疗难治性融合型胶质母细胞瘤成年患者中显示出持久疗效。
Neurooncol Adv. 2022 Apr 13;4(1):vdac046. doi: 10.1093/noajnl/vdac046. eCollection 2022 Jan-Dec.
9
Glioma targeted therapy: insight into future of molecular approaches.脑胶质瘤靶向治疗：分子靶向治疗的未来展望。
Mol Cancer. 2022 Feb 8;21(1):39. doi: 10.1186/s12943-022-01513-z.
10
Childhood Malignant Brain Tumors: Balancing the Bench and Bedside.儿童恶性脑肿瘤：兼顾基础研究与临床应用
Cancers (Basel). 2021 Dec 3;13(23):6099. doi: 10.3390/cancers13236099.
Significance of liquid biopsy in glioblastoma - A review.
液体活检在胶质母细胞瘤中的意义——综述。
J Biotechnol. 2019 Jun 10;298:82-87. doi: 10.1016/j.jbiotec.2019.04.011. Epub 2019 Apr 12.
4
Larotrectinib in NTRK-Rearranged Solid Tumors.拉罗替尼治疗NTRK重排实体瘤
Biochemistry. 2019 Mar 26;58(12):1555-1557. doi: 10.1021/acs.biochem.9b00126. Epub 2019 Mar 13.
5
Immunogenetics of glioblastoma: the future of personalized patient management.胶质母细胞瘤的免疫遗传学：个性化患者管理的未来
NPJ Precis Oncol. 2018 Dec 4;2:27. doi: 10.1038/s41698-018-0070-1. eCollection 2018.
6
Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors.综合基因组分析鉴定出神经内分泌肿瘤中的新型NTRK融合基因。
Oncotarget. 2018 Nov 9;9(88):35809-35812. doi: 10.18632/oncotarget.26260.
7
NTRK fusion-positive cancers and TRK inhibitor therapy.NTRK 融合阳性癌症和 TRK 抑制剂治疗。
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. doi: 10.1038/s41571-018-0113-0.
8
Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.病例报告：拉罗替尼治疗 TRK 融合驱动的高级别胶质瘤的显著临床和影像学反应。
Br J Cancer. 2018 Sep;119(6):693-696. doi: 10.1038/s41416-018-0251-2. Epub 2018 Sep 17.
9
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.新辅助拉罗替尼治疗局部晚期 TRK 融合肉瘤儿童患者。
Cancer. 2018 Nov 1;124(21):4241-4247. doi: 10.1002/cncr.31701. Epub 2018 Sep 11.
10
Molecular characterization of cancers with NTRK gene fusions.具有 NTRK 基因融合的癌症的分子特征。
Mod Pathol. 2019 Jan;32(1):147-153. doi: 10.1038/s41379-018-0118-3. Epub 2018 Aug 31.